Cargando…
Experience of targeted Usher exome sequencing as a clinical test
We show that massively parallel targeted sequencing of 19 genes provides a new and reliable strategy for molecular diagnosis of Usher syndrome (USH) and nonsyndromic deafness, particularly appropriate for these disorders characterized by a high clinical and genetic heterogeneity and a complex struct...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907913/ https://www.ncbi.nlm.nih.gov/pubmed/24498627 http://dx.doi.org/10.1002/mgg3.25 |
_version_ | 1782301681074044928 |
---|---|
author | Besnard, Thomas García-García, Gema Baux, David Vaché, Christel Faugère, Valérie Larrieu, Lise Léonard, Susana Millan, Jose M Malcolm, Sue Claustres, Mireille Roux, Anne-Françoise |
author_facet | Besnard, Thomas García-García, Gema Baux, David Vaché, Christel Faugère, Valérie Larrieu, Lise Léonard, Susana Millan, Jose M Malcolm, Sue Claustres, Mireille Roux, Anne-Françoise |
author_sort | Besnard, Thomas |
collection | PubMed |
description | We show that massively parallel targeted sequencing of 19 genes provides a new and reliable strategy for molecular diagnosis of Usher syndrome (USH) and nonsyndromic deafness, particularly appropriate for these disorders characterized by a high clinical and genetic heterogeneity and a complex structure of several of the genes involved. A series of 71 patients including Usher patients previously screened by Sanger sequencing plus newly referred patients was studied. Ninety-eight percent of the variants previously identified by Sanger sequencing were found by next-generation sequencing (NGS). NGS proved to be efficient as it offers analysis of all relevant genes which is laborious to reach with Sanger sequencing. Among the 13 newly referred Usher patients, both mutations in the same gene were identified in 77% of cases (10 patients) and one candidate pathogenic variant in two additional patients. This work can be considered as pilot for implementing NGS for genetically heterogeneous diseases in clinical service. |
format | Online Article Text |
id | pubmed-3907913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Wiley Periodicals |
record_format | MEDLINE/PubMed |
spelling | pubmed-39079132014-02-04 Experience of targeted Usher exome sequencing as a clinical test Besnard, Thomas García-García, Gema Baux, David Vaché, Christel Faugère, Valérie Larrieu, Lise Léonard, Susana Millan, Jose M Malcolm, Sue Claustres, Mireille Roux, Anne-Françoise Mol Genet Genomic Med Original Articles We show that massively parallel targeted sequencing of 19 genes provides a new and reliable strategy for molecular diagnosis of Usher syndrome (USH) and nonsyndromic deafness, particularly appropriate for these disorders characterized by a high clinical and genetic heterogeneity and a complex structure of several of the genes involved. A series of 71 patients including Usher patients previously screened by Sanger sequencing plus newly referred patients was studied. Ninety-eight percent of the variants previously identified by Sanger sequencing were found by next-generation sequencing (NGS). NGS proved to be efficient as it offers analysis of all relevant genes which is laborious to reach with Sanger sequencing. Among the 13 newly referred Usher patients, both mutations in the same gene were identified in 77% of cases (10 patients) and one candidate pathogenic variant in two additional patients. This work can be considered as pilot for implementing NGS for genetically heterogeneous diseases in clinical service. Wiley Periodicals 2014-01 2013-07-10 /pmc/articles/PMC3907913/ /pubmed/24498627 http://dx.doi.org/10.1002/mgg3.25 Text en © 2013 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Besnard, Thomas García-García, Gema Baux, David Vaché, Christel Faugère, Valérie Larrieu, Lise Léonard, Susana Millan, Jose M Malcolm, Sue Claustres, Mireille Roux, Anne-Françoise Experience of targeted Usher exome sequencing as a clinical test |
title | Experience of targeted Usher exome sequencing as a clinical test |
title_full | Experience of targeted Usher exome sequencing as a clinical test |
title_fullStr | Experience of targeted Usher exome sequencing as a clinical test |
title_full_unstemmed | Experience of targeted Usher exome sequencing as a clinical test |
title_short | Experience of targeted Usher exome sequencing as a clinical test |
title_sort | experience of targeted usher exome sequencing as a clinical test |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907913/ https://www.ncbi.nlm.nih.gov/pubmed/24498627 http://dx.doi.org/10.1002/mgg3.25 |
work_keys_str_mv | AT besnardthomas experienceoftargetedusherexomesequencingasaclinicaltest AT garciagarciagema experienceoftargetedusherexomesequencingasaclinicaltest AT bauxdavid experienceoftargetedusherexomesequencingasaclinicaltest AT vachechristel experienceoftargetedusherexomesequencingasaclinicaltest AT faugerevalerie experienceoftargetedusherexomesequencingasaclinicaltest AT larrieulise experienceoftargetedusherexomesequencingasaclinicaltest AT leonardsusana experienceoftargetedusherexomesequencingasaclinicaltest AT millanjosem experienceoftargetedusherexomesequencingasaclinicaltest AT malcolmsue experienceoftargetedusherexomesequencingasaclinicaltest AT claustresmireille experienceoftargetedusherexomesequencingasaclinicaltest AT rouxannefrancoise experienceoftargetedusherexomesequencingasaclinicaltest |